| PETRA: PErtuzumab and Trastuzumab Biosimilars Real Life Association for the First Line Treatment of HER2-positive Metastatic Breast Cancer, an Observational Prospective Multicenter Study (NCT04644406) | Hospices Civils de Lyon | 2020-12-01 |
| Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer (NCT02947685) | Alliance Foundation Trials, LLC. | 2017-06-21 |
| A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer (NCT02675231) | Eli Lilly and Company | 2016-05-23 |
| Neoadjuvant Nab-PTX and Trastuzumab for ER Negative and HER2 Positive Breast Cancer (NCT02598310) | Osaka Medical College | 2015-11-01 |
| Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer (NCT02492711) | MacroGenics | 2015-08-24 |
| T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA (NCT02326974) | Dana-Farber Cancer Institute | 2015-01-01 |
| A Study of Liposomal Doxorubicin+Docetaxel+Trastuzumab+Metformin in Operable and Locally Advanced HER2 Positive Breast Cancer (NCT02488564) | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 2014-12-17 |
| Neoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer (NCT02568839) | Thomas Hatschek | 2014-11-01 |
| Strain Imaging in Breast Cancer Patients Receiving Trastuzumab (NCT02080390) | University of Florida | 2014-09-01 |
| Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer (NCT02066532) | Dawn L. Hershman | 2014-06-01 |
| Chemotherapy for Elderly Patients Diagnosed With Localized HER2 Positive Breast Cancer (NCT02102438) | Instituto do Cancer do Estado de São Paulo | 2014-04-01 |
| Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto) (NCT01583426) | GBG Forschungs GmbH | 2012-07-01 |
| An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer (NCT01677455) | Synta Pharmaceuticals Corp. | 2012-07-01 |
| HER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1 (NCT01565200) | Jules Bordet Institute | 2012-05-01 |
| Primary Chemotherapy With Anthracycline Followed by Nab-paclitaxel and Trastuzumab (NCT01432223) | Osaka Medical College | 2011-09-01 |
| A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases (NCT01305941) | UNC Lineberger Comprehensive Cancer Center | 2011-09-01 |
| Study of Neoadjuvant Carboplatin, Eribulin and Trastuzumab for Operable HER2 Positive Breast Cancer (NCT01388647) | Vector Oncology | 2011-08-01 |
| Efficacy and Safety Study of Trastuzumab and Paclitaxel Based Regimens to Treat HER2-positive Breast Cancer (NCT01428414) | Zhimin Shao | 2011-08-01 |
| Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer (NCT01426880) | GBG Forschungs GmbH | 2011-08-01 |
| AUY922 With Lapatinib and Letrozole for ER+ HER2+ Advanced Breast Cancer (NCT01361945) | Texas Tech University Health Sciences Center, El Paso | 2011-07-01 |
| Neoadjuvant 5-fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Weekly Paclitaxel and Trastuzumab in Her2 Positive Breast Cancer (NCT01340430) | Lucia Del Mastro,MD | 2011-03-01 |
| Characteristics of Disseminated Her2+ Breast Cancer Patients Treated With Trastuzumab That Have Reached Complete, Partial Remission or Stabilization of Disease During More Than 3 Years (NCT01433926) | Asociación para el Progreso de la Oncología en Málaga | 2009-09-01 |
| A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast Cancer (NCT00788931) | Novartis Pharmaceuticals | 2008-12-01 |